Biogen Idec Inc., the largest biotech based in Massachusetts, is expanding its local campus to seven buildings housing 2,800 employees.

BIOGEN IDEC HIGHLIGHTS PROGRESS AND BREADTH OF PIPELINE PROGRAMS AT R&D DAY 20 late stage product candidates with potential to drive mid and long-term growth CAMBRIDGE, MA, March 25, 2009 - Biogen ...

Development of an experimental drug seen as a potential treatment for the progressive neurodegenerative disorder known as Lou Gehrig’s disease was halted Thursday after its maker, Biogen Idec ...

Biogen Idec may join the exodus of biotech companies leaving Cambridge, MA and move its corporate HQ on out to the suburbs.

They bear business cards, Powerpoint presentations, and rosy projections of success. They hope to persuade the Cambridge-based drug maker Biogen Idec Inc. — which vaulted to the top ranks of ...

The work of a biotechnology company like Biogen Idec–a Cambridge, Massachusetts-based company that specializes in medicines for people with neurodegenerative diseases, hematologic conditions and ...

CAMBRIDGE, Massachusetts (Reuters) - Biogen Idec Inc said on Thursday it has won a proxy fight against billionaire investor Carl Icahn, placing the biotechnology company on course to continue as ...

More cost savings will come via the shutdown of Biogen's San Diego facility--which has been part of Biogen since it bought Idec Pharmaceuticals in 2006--and consolidation of two Massachusetts ...

When activist investor Carl Icahn offered in October to acquire Biogen Idec of Cambridge, Massachusetts, for $23 billion, most figured he was hoping to start a bidding war by going public with ...

Biogen Inc on Wednesday said it had cinched a $900 million deal to resolve a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to ...